newsfilter
← Latest News
GlobeNewswire·

Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid Overdose

SANTA MONICA, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ:OPNT) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 16/461,354,